Health Care·Life Sciences Tools & Services·$6.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.10 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.10 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future performance. They highlighted ongoing investments in growth but did not provide specific metrics.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on long-term growth despite the current challenges.
Repligen Corp's earnings report showed a modest EPS of $0.10, but the lack of revenue details and guidance contributed to a significant stock decline of 8.52%. Investors may be concerned about the company's future performance given the absence of specific metrics and a cautious tone from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ICAHN ENTERPRISES L
Mar 3, 2014